Evidence map›Paper›PMID 34751518›Full record

ArticleBiotechnology progress2022

Identification and classification of host cell proteins during biopharmaceutical process development.

Louisa J Wilson, Will Lewis, Richard Kucia-Tran, Daniel G Bracewell

Open access · hybridAbstract read
In one paragraph

Article in Biotechnology progress, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Louisa J WilsonThe Advanced Centre for Biochemical Engineering, Department of Biochemical Engineering, University College London, London, UK.
Will LewisGlaxoSmithKline, Stevenage, Hertfordshire, UK.
Richard Kucia-TranGlaxoSmithKline, Stevenage, Hertfordshire, UK.
Daniel G BracewellThe Advanced Centre for Biochemical Engineering, Department of Biochemical Engineering, University College London, London, UK.ORCID 0000-0003-3866-3304
GlaxoSmithKline (United Kingdom) · GBBiochemical Society · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As significant improvements in volumetric antibody productivity have been achieved by advances in upstream processing over the last decade, and harvest material has become progressively more difficult to recover with these intensified upstream operations, the segregation of upstream and downstream processing has remained largely unchanged. By integrating upstream and downstream process development, product purification issues are given consideration during the optimization of upstream operating conditions, which mitigates the need for extensive and expensive clearance strategies downstream. To investigate the impact of cell culture duration on critical quality attributes, CHO-expressed IgG1 was cultivated in two 2 L bioreactors with samples taken on days 8, 10, 13, 15, and 17. The material was centrifuged, filtered and protein A purified on a 1 ml HiTrap column. Host cell protein (HCP) identification by mass spectrometry (MS) was applied to this system to provide insights into cellular behavior and HCP carryover during protein A purification. It was shown that as cultivation progressed from day 8 to 17 and antibody titer increased, product quality declined due to an increase in post-protein A HCPs (from 72 to 475 peptides detected by MS) and a decrease in product monomer percentage (from 98% to 95.5%). Additionally, the MS data revealed an increase in the abundance of several classes of post-protein A HCPs (e.g., stress response proteins and indicators of cell age), particularly on days 15 and 17 of culture, which were associated with significant increases in total overall HCP levels. This provides new insight into the specific types of HCPs that are retained during mAb purification and may be used to aid process development strategies.

Indexed as

Biological ProductsImmunoglobulin GAnimalsCHO CellsCricetinaeCricetulusMass SpectrometryBiological ProductsImmunoglobulin Gdownstream processinghost cell proteinsmass spectrometrymonoclonal antibodiesproduct qualityupstream processing

Identifiers

PMID34751518
PMCPMC11475378
OpenAlexW3214540116

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.